Drugs / methylphenidate transdermal system
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00499863 | Jul 2007 → May 2008 | attention deficit-hyperactivity disorder | Noven Therapeutics | Completed | Met primary |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-06 | Noven Therapeutics | Noven Provides Update on Daytrana® (methylphenidate transdermal system), CII Supply and Ongoing Efforts to Resolve Shortage noven.com ↗ |
| 2010-10-01 | Noven Therapeutics | Noven Completes Acquisition of Daytrana® Methylphenidate Transdermal System (Cii) From Shire noven.com ↗ |
| 2010-08-10 | Noven Therapeutics | Noven To Acquire Daytrana® Methylphenidate Transdermal System From Shire noven.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | methylphenidate transdermal system | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00499863 ↗ |
| Known as | MTS | “INTRODUCTION: The current report evaluates the efficacy and safety of methylphenidate transdermal system (MTS) compared with placebo transdermal system (PTS) in adolescents...” PMID 20625364 ↗ Jul 2010 |